Malvern-based Recro Sets Annual Revenue Record; Reports 2019 Revenues of $99.2 Million
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a high-performing, revenue generating contract development and manufacturing organization (CDMO), recently reported financial results for the year ended December 31, 2019.
Read More